地骨皮甲素通过IL-6/JAK/STAT3/DAO通路抑制内源性草酸合成缓解肾结石
研究利用果蝇模型筛选中药及其活性成分,发现地骨皮通过JNK/Upd3/JAK/STAT通路下调DAO表达减少内源性草酸合成,地骨皮甲素(KuA)为主要活性成分;小鼠和人肾小管细胞实验证实KuA通过激活肝JAK/STAT3上调IL-6减少晶体沉积。
要点
- 地骨皮甲素(KuA)是地骨皮抗肾结石的主要活性成分。
- KuA通过激活IL-6/JAK/STAT3通路下调DAO减少内源性草酸合成。
- 果蝇模型可用于筛选中药抗肾结石活性成分及机制研究。
核心结论
- 地骨皮甲素(KuA)通过IL-6/JAK/STAT3通路抑制内源性草酸合成,减少草酸钙晶体沉积,是治疗肾结石的潜在先导化合物。
- 研究揭示了炎症通路与内源性草酸代谢在肾结石发病中的交互作用。
研究设计与样本
- 研究采用果蝇模型筛选中药及其活性成分,并用固相色谱结合LC-MS分离鉴定候选化合物。
- 利用果蝇遗传工具操纵相关基因表达探索地骨皮和KuA的机制。
- 采用乙醛酸诱导的小鼠肾结石模型和人肾小管细胞体外模型验证KuA疗效和机制。
- 通过评估肾小管损伤、晶体沉积和黏附评价KuA治疗作用,用RT-qPCR和western blot检测细胞和小鼠表达及磷酸化水平。
主要发现
- 地骨皮通过激活JNK/Upd3/JAK/STAT信号级联,下调果蝇马氏管星形细胞中D-氨基酸氧化酶(DAO)基因表达,减少内源性草酸合成,强效抑制草酸钙结石形成。
- KuA被鉴定为介导上述作用的主要生物活性成分。
- 小鼠模型和人细胞实验证实KuA通过激活肝JAK/STAT3通路、上调IL-6,减少尿液晶体沉积,预防哺乳动物草酸钙肾结石。
临床怎么用
- 地骨皮及其活性成分KuA可能作为肾结石治疗的候选中药,尤其针对内源性草酸合成相关机制。
- 果蝇模型可作为中药治疗机制研究的高效筛选工具。
- 临床转化前需进一步开展药代动力学、毒理学及人体临床试验验证。
局限性
- 研究主要基于果蝇和小鼠模型及体外细胞实验,尚缺乏人体临床数据。
- KuA的具体剂量、安全性和长期疗效未在原文中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recurrent nature and socioeconomic burden of nephrolithiasis demand effective treatments. Delineating the crosstalk between inflammatory processes and the endogenous oxalate metabolism pathway, which underpins nephrolithiasis pathogenesis, is essential for advancing treatment strategies. PURPOSE: We aim to screen therapeutic Chinese herbal remedies and their bioactive constituents for kidney stone treatment using a fruit fly model, followed by efficacy and mechanism validation in a rodent nephrolithiasis model as well as in vitro human cell culture model. STUDY DESIGN AND METHODS: We developed a fruit fly model to screen for efficient traditional Chinese medicine herbs and their active compounds for kidney stone treatment. Candidate active compounds from efficient herbs were separated and identified by solid-phase chromatography coupled with LC-MS analysis. Fruit fly genetic tools were employed to manipulate the expression of related genes to explore the therapeutic mechanisms of the Lycii Cortex and kukoamine A (KuA). To confirm the therapeutic effects and mechanisms of KuA for mammalian nephrolithiasis, mouse model of glyoxylate-induced kidney stone and human renal tubular cells were used. The therapeutic role of kukoamine A in nephrolithiasis was evaluated by assessing tubular injury, crystal deposition, and adhesion. The level of expression and phosphorylation in cells and mice was assessed using RT-qPCR and western blot. RESULTS: Our findings indicate that Lycii Cortex potently inhibits calcium oxalate stone formation via activation of the JNK/Upd3/JAK/STAT signaling cascade, resulting in diminished endogenous oxalate synthesis by downregulating D-amino acid oxidase (DAO) gene expression, predominantly in fruit fly Malpighian tube stellate cells. KuA was identified as the principal bioactive constituent mediating these effects. Both mouse models and human cell assays confirmed KuA's efficacy in preventing calcium oxalate nephrolithiasis in mammals, through hepatic JAK/STAT3 pathway activation and upregulation of IL-6, culminating in reduced urinary crystal deposition. CONCLUSION: Our research underscores the potential of kukoamine A as a lead compound in treating nephrolithiasis and reveals the interplay between the IL-6/JAK/STAT3 inflammatory pathway and endogenous oxalate metabolism in nephrolithiasis pathogenesis. Additionally, it highlights the utility of the fruit fly model as a powerful tool for deciphering the therapeutic mechanisms of traditional Chinese herbs.
引用
- Ju Y, Du M, Wang Z, et al. Kukoamine A alleviates nephrolithiasis by inhibiting endogenous oxalate synthesis via the IL-6/JAK/STAT3/DAO signaling pathway. Phytomedicine. 2024. PMID: 39461201. doi:10.1016/j.phymed.2024.156145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。